Good morning :)
Place Order
Add to Watchlist

Jagsonpal Pharmaceuticals Ltd

JAGSNPHARM Share Price

229.560.00% (+0.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health Care
Pharmaceuticals
Smallcap

With a market cap of ₹1,527 cr, stock is ranked 1,256

High Risk

Stock is 4.66x as volatile as Nifty

JAGSNPHARM Stock Scorecard

Performance

High

The creamy layer - amongst the top performing stocks

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health Care
Pharmaceuticals
Smallcap

With a market cap of ₹1,527 cr, stock is ranked 1,256

High Risk

Stock is 4.66x as volatile as Nifty

JAGSNPHARM Performance & Key Metrics

JAGSNPHARM Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
27.608.151.08%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
36.516.490.80%

JAGSNPHARM Analyst Ratings & Forecast

—
Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

JAGSNPHARM Company Profile

Jagsonpal Pharmaceuticals Limited is engaged in pharmaceutical business. It specializes in developing and manufacturing bulk drugs and pharmaceutical formulations.

JAGSNPHARM Similar Stocks (Peers)

Compare with peers Compare with peers 

JAGSNPHARM Similar Stocks (Peers)

Compare with peers Compare with peers 
Sun Pharmaceutical Industries Ltd
SUNPHARMA
PE Ratio
36.83
36.83
1Y Return
10.07%
10.07%
Buy Reco %
87.88
87.88
Cipla Ltd
CIPLA
PE Ratio
22.94
22.94
1Y Return
0.60%
0.60%
Buy Reco %
73.33
73.33
Torrent Pharmaceuticals Ltd
TORNTPHARM
PE Ratio
59.32
59.32
1Y Return
18.79%
18.79%
Buy Reco %
70.83
70.83
Dr Reddy's Laboratories Ltd
DRREDDY
PE Ratio
18.70
18.70
1Y Return
0.26%
0.26%
Buy Reco %
55.17
55.17
Zydus Lifesciences Ltd
ZYDUSLIFE
PE Ratio
22.13
22.13
1Y Return
7.37%
7.37%
Buy Reco %
46.43
46.43
Compare with Peers

JAGSNPHARM Sentiment Analysis

JAGSNPHARM Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

JAGSNPHARM Stock Summary · May 2025

Jagsonpal Pharmaceuticals is strategically enhancing its operational efficiency and market positioning following a significant transformation since June 2022. With a focus on niche markets and a diversified product portfolio, the company anticipates a revenue growth of 12%-15% driven by new product launches and optimized pricing strategies. Despite facing challenges such as increased competition and a decline in certain product lines, management remains optimistic about margin improvements and cash generation, having successfully reduced working capital needs significantly. The commitment to disciplined execution and transparent communication underscores their proactive approach to building stakeholder trust and navigating market dynamics effectively. As they prioritize acquisitions aligned with their therapeutic focus, the company is poised for sustainable growth while maintaining a robust financial foundation.

JAGSNPHARM Stock Growth Drivers
JAGSNPHARM Stock Growth Drivers
7
  • Strong Financial Performance

    Jagsonpal Pharmaceuticals has reported significant financial achievements, including operating margins exceeding 21%, a reduction in

  • Successful Strategic Initiatives

    The company has undergone a significant transformation since June 2022, following a major acquisition that

JAGSNPHARM Stock Challenges
JAGSNPHARM Stock Challenges
5
  • Decline in Divatrone Revenue

    The Dydrogesterone (Divatrone) product has experienced a significant decline in performance, with monthly revenues dropping

  • Weak Q4 Performance

    The company typically experiences weaker performance in Q4 due to reduced stockist purchases, a common

JAGSNPHARM Forecast

JAGSNPHARM Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

JAGSNPHARM

JAGSNPHARM

Income

Balance Sheet

Cash Flow

JAGSNPHARM Income Statement

JAGSNPHARM Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 12.98%, vs industry avg of 10.2%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.06% to 0.07%

Higher than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 47.68%, vs industry avg of 20.11%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue157.14126.99168.26161.10192.34221.01242.44217.98296.59300.09
Raw Materialssubtract67.3465.1953.4354.9475.5083.3588.0476.08217.65221.15
Power & Fuel Costsubtract2.121.001.410.640.520.470.290.17
Employee Costsubtract40.9541.8846.6150.3753.9857.6865.1861.80
Selling & Administrative Expensessubtract30.1927.5632.2338.3431.8842.5041.6641.09
Operating & Other expensessubtract-2.502.0123.815.756.998.5610.856.50
Depreciation/Amortizationsubtract1.990.321.021.131.091.531.211.668.138.13
Interest & Other Itemssubtract2.640.660.750.510.510.290.410.810.960.97
Taxes & Other Itemssubtract2.53-0.081.781.544.827.788.097.4114.5014.50
EPS1.81-1.761.101.202.602.884.083.418.268.37
DPS0.040.040.100.200.401.602.002.002.502.00
Payout ratio0.02—0.090.170.150.560.490.590.300.24
See Costs

JAGSNPHARM Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF

Investor Presentation

Feb 22PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF
FY 2016FY 2016

Annual report

PDF
FY 2015FY 2015

Annual Report Unavailable

FY 2014FY 2014

Annual report

PDF
 

JAGSNPHARM Stock Peers

JAGSNPHARM Past Performance & Peer Comparison

JAGSNPHARM Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation-basic on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Jagsonpal Pharmaceuticals Ltd27.598.151.08%
Sun Pharmaceutical Industries Ltd36.836.000.95%
Cipla Ltd22.943.871.07%
Torrent Pharmaceuticals Ltd59.3216.530.96%

JAGSNPHARM Stock Price Comparison

Compare JAGSNPHARM with any stock or ETF
Compare JAGSNPHARM with any stock or ETF
JAGSNPHARM
Loading...

JAGSNPHARM Holdings

JAGSNPHARM Shareholdings

JAGSNPHARM Promoter Holdings Trend

JAGSNPHARM Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

JAGSNPHARM Institutional Holdings Trend

JAGSNPHARM Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

JAGSNPHARM Shareholding Pattern

JAGSNPHARM Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding67.78%0.00%0.00%2.10%30.11%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

JAGSNPHARM Shareholding History

JAGSNPHARM Shareholding History

Dec '23MarJunSepDec '24Mar0.53%0.73%1.10%2.30%2.10%2.10%

JAGSNPHARM Insider Trades & Bulk Stock Deals

JAGSNPHARM Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing JAGSNPHARM stock

smallcases containing JAGSNPHARM stock

Looks like this stock is not in any smallcase yet.

JAGSNPHARM Events

JAGSNPHARM Events

JAGSNPHARM Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

JAGSNPHARM has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 1.08%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹10.82 every year

Dividends

Corp. Actions

Announcements

Legal Orders

JAGSNPHARM Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

JAGSNPHARM has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 1.08%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹10.82 every year

JAGSNPHARM Upcoming Dividends

JAGSNPHARM Upcoming Dividends

No upcoming dividends are available

JAGSNPHARM Past Dividends

JAGSNPHARM Past Dividends

Cash Dividend

Ex DateEx DateSep 6, 2024

Final
Final | Div/Share: ₹5.00

Dividend/Share

₹5.00

Ex DateEx Date

Sep 6, 2024

Cash Dividend

Ex DateEx DateAug 21, 2023

Final
Final | Div/Share: ₹5.00

Dividend/Share

₹5.00

Ex DateEx Date

Aug 21, 2023

Cash Dividend

Ex DateEx DateOct 29, 2021

Interim
Interim | Div/Share: ₹4.00

Dividend/Share

₹4.00

Ex DateEx Date

Oct 29, 2021

Cash Dividend

Ex DateEx DateSep 22, 2021

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 22, 2021

Cash Dividend

Ex DateEx DateSep 22, 2020

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Sep 22, 2020

JAGSNPHARM Stock News & Opinions

JAGSNPHARM Stock News & Opinions

Corporate
Jagsonpal Pharmaceuticals allots 53,000 equity shares under ESOP

Jagsonpal Pharmaceuticals has allotted 53,000 equity shares under ESOP on 11 June 2025. With this allotment, the paid up equity share capital has increased from Rs. 13,29,46,960 (constituting of 6,64,73,480 equity shares of Rs. 2/- each) to Rs. 13,30,52,960 (constituting of 6,65,26,480 equity shares of Rs. 2/- each).Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Board of Jagsonpal Pharmaceuticals recommends final dividend

Jagsonpal Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 6 May 2025, inter alia, have recommended the final dividend of Rs 2.5 per equity Share (i.e. 125%) , subject to the approval of the shareholders.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Jagsonpal Pharmaceuticals standalone net profit rises 85.35% in the March 2025 quarter

Net profit of Jagsonpal Pharmaceuticals rose 85.35% to Rs 6.58 crore in the quarter ended March 2025 as against Rs 3.55 crore during the previous quarter ended March 2024. Sales rose 34.65% to Rs 58.56 crore in the quarter ended March 2025 as against Rs 43.49 crore during the previous quarter ended March 2024. For the full year,net profit rose 146.48% to Rs 55.36 crore in the year ended March 2025 as against Rs 22.46 crore during the previous year ended March 2024. Sales rose 28.76% to Rs 268.72 crore in the year ended March 2025 as against Rs 208.70 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales58.5643.49 35 268.72208.70 29 OPM %14.896.12 -19.0011.05 - PBDT11.234.93 128 58.3031.53 85 PBT8.924.53 97 50.1729.87 68 NP6.583.55 85 55.3622.46 146 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals to announce Quarterly Result

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 6 May 2025.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals allots 39,850 equity shares under ESOP

Jagsonpal Pharmaceuticals has allotted 39,850 equity shares under ESOP. With this allotment, the paid up equity share capital has increased to Rs. 13,28,76,960 (constituting of 6,64,38,480 equity shares of Rs. 2/- each).Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals allots 11,575 equity shares under ESOP

Jagsonpal Pharmaceuticals has allotted 11,575 equity shares under ESOP. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs. 13,27,74,110 (constituting of 6,63,87,055 equity shares of Rs. 2/- each) to Rs. 13,27,97,260 (constituting of 6,63,98,630 equity shares of Rs. 2/- each). Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals allots 22,150 equity shares under ESOP

Jagsonpal Pharmaceuticals has allotted 22,150 equity shares of Rs. 2/- each under JPL ESOP 2022, to the eligible employee of the Company, upon exercise of vested options. Consequent to the above allotment, the paid-up share capital of the Company has increased from Rs. 13,27,29,810 (constituting of 6,63,64,905 equity shares of Rs. 2/- each) to Rs. 13,27,74,112 (constituting of 6,63,87,056 equity shares of Rs. 2/- each).Powered by Capital Market - Live

4 months agoCapital Market - Live
Spotlight
Jagsonpal Pharma gains after reporting strong Q3 numbers

Revenue from operations surged 56.7% to Rs 74.03 crore recorded in the quarter ended 31 December 2024. Profit before exceptional items and tax stood at Rs 15.48 in Q3 FY24, steeply higher than Rs 5.27 crore posted in Q3 FY23. The company reported an exceptional item of Rs 23.18 crore during the quarter. The company's operating EBITDA surged by 185% to Rs 171 crore in Q3 FY25, compared to Rs 60 crore recorded in the same quarter last year. The EBITDA margin also improved to 23.1% in Q3 FY25, up from 12.8% in Q3 FY24. On nine-month basis, the company's net profit climbed 158% to Rs 48.78 crore on 27.2% increase in revenue to Rs 210.16 crore in 9M FY25 over 9M FY24. The company reported a strong balance sheet, having concluded the sale of its Faridabad facility for Rs 41 crore, resulting in exceptional income during Q3 FY25. As of 31 December 2024, the company maintains a robust cash balance of Rs 132.1 crore. Regarding its successful acquisition integration, the company stated that the integration of the acquired business is progressing well. Q3 FY25 marks the second full quarter of operations, with performance aligning with expectations. Jagsonpal Pharmaceuticals is engaged in the business of manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients. Powered by Capital Market - Live

5 months agoCapital Market - Live
Earnings
Jagsonpal Pharmaceuticals standalone net profit rises 707.83% in the December 2024 quarter

Net profit of Jagsonpal Pharmaceuticals rose 707.83% to Rs 31.99 crore in the quarter ended December 2024 as against Rs 3.96 crore during the previous quarter ended December 2023. Sales rose 56.74% to Rs 74.03 crore in the quarter ended December 2024 as against Rs 47.23 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales74.0347.23 57 OPM %21.387.18 - PBDT17.905.68 215 PBT15.495.27 194 NP31.993.96 708 Powered by Capital Market - Live

5 months agoCapital Market - Live
Corporate
Jagsonpal Pharmaceuticals to declare Quarterly Result

Jagsonpal Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 22 January 2025.Powered by Capital Market - Live

5 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) today?

    The share price of JAGSNPHARM as on 2nd July 2025 is ₹229.56. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?

    The past returns of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share are
    • Past 1 week: 4.13%
    • Past 1 month: -5.12%
    • Past 3 months: 0.75%
    • Past 6 months: -13.19%
    • Past 1 year: 70.37%
    • Past 3 years: 84.77%
    • Past 5 years: 1375.32%

  3. What are the peers or stocks similar to Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)?

    The peers or stocks similar to Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) include:

  4. What is the dividend yield % of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?

    The current dividend yield of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is 1.08.

  5. What is the market cap of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹1527.18 Cr as of 2nd July 2025.

  6. What is the 52 week high and low of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) share?

    The 52-week high of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is ₹328.04 and the 52-week low is ₹130.48.

  7. What is the PE and PB ratio of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) stock?

    The P/E (price-to-earnings) ratio of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) is 27.59. The P/B (price-to-book) ratio is 8.15.

  8. Which sector does Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) belong to?

    Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) shares?

    You can directly buy Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) shares on Tickertape. Simply sign up, connect your demat account and place your order.